Design of Next-Generation G Protein-Coupled Receptor Drugs: Linking Novel Pharmacology and in Vivo Animal Models

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 535-559

  Bradley, Sophie J ^a   Tobin, Andrew B ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Chemical genetics; Drug discovery; G protein coupled receptor; Optogenetics; Stimulus bias; Transgenic

Indexed keywords

AC 42; ADENOSINE A1 RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BUCINDOLOL; CARVEDILOL; DOPAMINE 1 RECEPTOR; ENDOTHELIN B RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR ANTAGONIST; LIGAND; LY 2119620; MU OPIATE RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; PARTIAL AGONIST; SALBUTAMOL; SALMETEROL; SEROTONIN 1B RECEPTOR; TAK 879; THRX 160206; UNCLASSIFIED DRUG; UNINDEXED DRUG; VCP 171; VCP 746; XANOMELINE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM;

ALLOSTERISM; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHEMICAL GENETICS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; GENE INACTIVATION; GENE TARGETING; GENETIC MODEL; HUMAN; IN VIVO STUDY; LIGAND BINDING; MOUSE MODEL; NEXT GENERATION SEQUENCING; NONHUMAN; OPTOGENETICS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION; ANIMAL; DRUG DEVELOPMENT; METABOLISM; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, ANIMAL; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84954091769     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-140012     Document Type: Article

References (159)

1. Kobilka B. 2013. The structural basis of G-protein-coupled receptor signaling (Nobel Lecture). Angew. Chem. 52:6380-88
2. Lefkowitz RJ. 2013. A brief history of G-protein coupled receptors (Nobel Lecture). Angew. Chem. 52:6366-78
3. Audet M, Bouvier M. 2012. Restructuring G-protein-coupled receptor activation. Cell 151:14-23
4. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. 2013. Molecular signatures of G-protein-coupled receptors. Nature 494:185-94
5. Nygaard R, Zou Y, Dror RO,Mildorf TJ, ArlowDH, et al. 2013. The dynamic process of 2-adrenergic receptor activation. Cell 152:532-42
6. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, et al. 2011. Crystal structure of the2 adrenergic receptor-Gs protein complex. Nature 477:549-55
7. Foord SM, BonnerTI, Neubig RR, RosserEM, Pin JP, et al. 2005. InternationalUnion of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol. Rev. 57:279-88
8. Azevedo MF, Sanders PR, Krejany E, Nie CQ, Fu P, et al. 2013. Inhibition of Plasmodium falciparum CDPK1 by conditional expression of its J-domain demonstrates a key role in schizont development. Biochem. J. 452:433-41
9. Schlyer S, Horuk R. 2006. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov. Today 11:481-93
10. Congreve M, Langmead CJ, Mason JS, Marshall FH. 2011. Progress in structure based drug design for G protein-coupled receptors. J. Med. Chem. 54:4283-311
11. Hopkins AL, Groom CR. 2002. The druggable genome. Nat. Rev. Drug Discov. 1:727-30
12. Overington JP, Al-Lazikani B, Hopkins AL. 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5:993-96
13. Arrowsmith J. 2011. Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10:328-29
14. Arrowsmith J. 2011. Trial watch: Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10:87
15. Lipworth BJ, McDevitt DG. 1992. Inhaled2-adrenoceptor agonists in asthma: help or hindrance? Br. J. Clin. Pharmacol. 33:129-38
16. Leurs R, Church MK, Taglialatela M. 2002. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin. Exp. Allergy: J. Br. Soc. Allergy Clin. Immunol. 32:489-98
17. Deakin M, Williams JG. 1992. Histamine H2-receptor antagonists in peptic ulcer disease: efficacy in healing peptic ulcers. Drugs 44:709-19
18. Bodick NC,OffenWW,Levey AI, Cutler NR, Gauthier SG, et al. 1997. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54:465-73
19. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, et al. 2008. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165:1033-39
20. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, et al. 1998. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res. 795:179-90
21. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, et al. 2012. Structure of the humanM2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:547-51
22. Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, et al. 2012. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482:552-56
23. Kruse AC, Weiss DR, Rossi M, Hu J, Hu K, et al. 2013. Muscarinic receptors as model targets and antitargets for structure-based ligand discovery. Mol. Pharmacol. 84(4):528-40
24. May LT, Avlani VA, Sexton PM, Christopoulos A. 2004. Allosteric modulation of G protein-coupled receptors. Curr. Pharm. Des. 10:2003-13
25. May LT, Leach K, Sexton PM, Christopoulos A. 2007. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47:1-51
26. Langmead CJ, Christopoulos A. 2014. Functional and structural perspectives on allosteric modulation of GPCRs. Curr. Opin. Cell Biol. 27:94-101
27. Langmead CJ. 2012. Ligand properties and behaviours in an allosteric age. Trends Pharmacol. Sci. 33:621-22
28. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, et al. 2011. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80:367-77
29. Kenakin T. 1995. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 16:232-38
30. Bradley SJ, Riaz SA, Tobin AB. 2014. Employing novel animal models in the design of clinically efficacious GPCR ligands. Curr. Opin. Cell Biol. 27:117-25
31. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, et al. 2011. Structure and function of an irreversible agonist-2 adrenoceptor complex. Nature 469:236-40
32. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, et al. 2013. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101-6
33. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, et al. 2014. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513:124-27
34. Yabuki C, Komatsu H, Tsujihata Y, Maeda R, Ito R, et al. 2013. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLOS ONE 8:e76280
35. Dror RO, Arlow DH, Maragakis P, Mildorf TJ, Pan AC, et al. 2011. Activation mechanism of the2-adrenergic receptor. PNAS 108:18684-89
36. Dror RO, Jensen MO, Borhani DW, Shaw DE. 2010. Exploring atomic resolution physiology on a femtosecond to millisecond timescale using molecular dynamics simulations. J. Gen. Physiol. 135:555-62
37. Ghosh E, Kumari P, Jaiman D, Shukla AK. 2015. Methodological advances: The unsung heroes of the GPCR structural revolution. Nat. Rev. Mol. Cell Biol. 16:69-81
38. Congreve M, Rich RL, Myszka DG, Figaroa F, Siegal G, Marshall FH. 2011. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. Methods Enzymol. 493:115-36
39. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, et al. 2011. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521-25
40. Dore AS, Robertson N, Errey JC, Ng I, Hollenstein K, et al. 2011. Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19:1283-93
41. Zhukov A, Andrews SP, Errey JC, Robertson N, Tehan B, et al. 2011. Biophysical mapping of the adenosine A2A receptor. J. Med. Chem. 54:4312-23
42. Patching SG. 2014. Surface plasmon resonance spectroscopy for characterisation of membrane proteinligand interactions and its potential for drug discovery. Biochim. Biophys. Acta 1838:43-55
43. Valant C, Robert Lane J, Sexton PM, Christopoulos A. 2012. The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52:153-78
44. Steinfeld T,MammenM, Smith JA, Wilson RD, Jasper JR. 2007. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol. Pharmacol. 72:291-302
45. Griffin MT, Figueroa KW, Liller S, Ehlert FJ. 2007. Estimation of agonist activity atGprotein-coupled receptors: Analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. J. Pharmacol. Exp. Ther. 321:1193-207
46. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, et al. 2008. A novel mechanism of G protein-coupled receptor functional selectivity: muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283:29312-21
47. Avlani VA, Langmead CJ,Guida E, Wood MD, Tehan BG, et al. 2010. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol. Pharmacol. 78:94-104
48. Jacobson MA, Kreatsoulas C, Pascarella DM, O'Brien JA, Sur C. 2010. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1-(2-methylbenzyl)-1,4-bipiperidin-4-yl]-1,3-dihydro-2Hbenzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site. Mol. Pharmacol. 78:648-57
49. Keov P, Valant C, Devine SM, Lane JR, Scammells PJ, et al. 2013. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at theM1 muscarinic acetylcholine receptor. Mol. Pharmacol. 84:425-37
50. Langmead CJ, AustinNE, Branch CL, Brown JT, Buchanan KA, et al. 2008. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 154:1104-15
51. Yang Z, Cerniway RJ, Byford AM, Berr SS, French BA, Matherne GP. 2002. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 282:H949-55
52. Mustafa SJ, Morrison RR, Teng B, Pelleg A. 2009. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb. Exp. Pharmacol. 193:161-88
53. Valant C, May LT, Aurelio L, Chuo CH, White PJ, et al. 2014. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. PNAS 111:4614-19
54. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, Scammells PJ. 2009. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J. Med. Chem. 52:4543-47
55. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr. 2012. TRV120027, a novel arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ. Heart Fail. 5:627-34
56. Violin JD, Lefkowitz RJ. 2007. Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28:416-22
57. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, et al. 2007. A unique mechanism of blocker action: carvedilol stimulates arrestin signaling. PNAS 104:16657-62
58. Kenakin T, Christopoulos A. 2013. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12:205-16
59. Kenakin T,Watson C,Muniz-Medina V, Christopoulos A, Novick S. 2012. A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3:193-203
60. van der Westhuizen ET, Breton B, Christopoulos A, Bouvier M. 2014. Quantification of ligand bias for clinically relevant2-adrenergic receptor ligands: implications for drug taxonomy. Mol. Pharmacol. 85:492-509
61. Warne T, Edwards PC, Leslie AG, Tate CG. 2012. Crystal structures of a stabilized1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20:841-49
62. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. 2012. Molecular mechanism of arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52:179-97
63. Butcher AJ, Prihandoko R, Kong KC, McWilliams P, Edwards JM, et al. 2011. Differential G-proteincoupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol. Chem. 286:11506-18
64. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, et al. 2011. Distinct phosphorylation sites on the2-adrenergic receptor establish a barcode that encodes differential functions of arrestin. Sci. Signal. 4:ra51
65. Tobin AB, Butcher AJ, Kong KC. 2008. Location, location, location. . . site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol. Sci. 29:413-20
66. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ. 2009. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. PNAS 106:9649-54
67. Tobin AB. 2008. G-protein-coupled receptor phosphorylation: where, when and by whom. Br. J. Pharmacol. 153(Suppl. 1):S167-76
68. Torrecilla I, Spragg EJ, Poulin B, McWilliams PJ, Mistry SC, et al. 2007. Phosphorylation and regulation of a G protein-coupled receptor by protein kinase CK2. J. Cell Biol. 177:127-37
69. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. 2007. Arrestins and cell signaling. Annu. Rev. Physiol. 69:483-510
70. Shukla AK, Manglik A, Kruse AC, Xiao K, Reis RI, et al. 2013. Structure of active arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 497:137-41
71. Xiao K, Shenoy SK, Nobles K, Lefkowitz RJ. 2004. Activation-dependent conformational changes in arrestin 2. J. Biol. Chem. 279:55744-53
72. Nobles KN, Guan Z, Xiao K, Oas TG, Lefkowitz RJ. 2007. The active conformation of arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of arrestins1 and-2. J. Biol. Chem. 282:21370-81
73. Capecchi MR. 2005. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat. Rev. Genet. 6:507-12
74. Thomas KR, Folger KR, Capecchi MR. 1986. High frequency targeting of genes to specific sites in the mammalian genome. Cell 44:419-28
75. Kobilka BK, Frielle T, Dohlman HG, Bolanowski MA, Dixon RA, et al. 1987. Delineation of the intronless nature of the genes for the human and hamster2-adrenergic receptor and their putative promoter regions. J. Biol. Chem. 262:7321-27
76. Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, et al. 1986. Cloning of the gene and cDNA for mammalian adrenergic receptor and homology with rhodopsin. Nature 321:75-79
77. Lefkowitz RJ. 2004. Historical review: A brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25:413-22
78. Xu M, Hu XT, Cooper DC, Moratalla R, Graybiel AM, et al. 1994. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79:945-55
79. Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, et al. 1994. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79:729-42
80. Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, et al. 1994. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79:1267-76
81. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, Tonegawa S. 1994. Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell 79:365-75
82. Saudou F, Amara DA, Dierich A, LeMeur M, Ramboz S, et al. 1994. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 265:1875-78
83. Rohrer DK, Kobilka BK. 1998. G protein-coupled receptors: functional and mechanistic insights through altered gene expression. Physiol. Rev. 78:35-52
84. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, et al. 1995. Regulation of blood pressure by the type 1A angiotensin II receptor gene. PNAS 92:3521-25
85. Coffman TM. 1997. A genetic approach for studying the physiology of the type 1A (AT1A) angiotensin receptor. Semin. Nephrol. 17:404-11
86. Sora I, TakahashiN, FunadaM,Ujike H, Revay RS, et al. 1997. Opiate receptor knockout mice define receptor roles in endogenous nociceptive responses and morphine-induced analgesia. PNAS 94:1544-49
87. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, et al. 1996. Cardiovascular regulation in mice lacking2-adrenergic receptor subtypes b and c. Science 273:803-5
88. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. 1996. Central hypotensive effects of the2a-adrenergic receptor subtype. Science 273:801-3
89. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, et al. 1997. Decreased blood pressure response in mice deficient of the1b-adrenergic receptor. PNAS 94:11589-94
90. Rohrer DK, Chruscinski A, Schauble EH, BernsteinD,Kobilka BK. 1999. Cardiovascular andmetabolic alterations in mice lacking both1-and2-adrenergic receptors. J. Biol. Chem. 274:16701-8
91. Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, et al. 1995. Targeted disruption of the3-adrenergic receptor gene. J. Biol. Chem. 270:29483-92
92. Bryson-Richardson RJ, Logan DW, Currie PD, Jackson IJ. 2004. Large-scale analysis of gene structure in rhodopsin-like GPCRs: evidence for widespread loss of an ancient intron. Gene 338:15-23
93. Tong H, Bernstein D,Murphy E, Steenbergen C. 2005. The role of adrenergic receptor signaling in cardioprotection. FASEB J. 19:983-85
94. Duttaroy A, Zimliki CL, Gautam D, Cui Y,Mears D, Wess J. 2004. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished inM3 muscarinic acetylcholine receptor-deficient mice. Diabetes 53:1714-20
95. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, et al. 2001. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410:207-12
96. Gautam D, Gavrilova O, Jeon J, Pack S, JouW, et al. 2006. Beneficial metabolic effects ofM3 muscarinic acetylcholine receptor deficiency. Cell Metab. 4:363-75
97. Gautam D, Han SJ, Hamdan FF, Jeon J, Li B, et al. 2006. A critical role for cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 3:449-61
98. Montmayeur JP, Bausero P, Amlaiky N, Maroteaux L, Hen R, Borrelli E. 1991. Differential expression of the mouse D2 dopamine receptor isoforms. FEBS Lett. 278:239-43
99. Pothos EN,Davila V, SulzerD. 1998. Presynaptic recording of quanta frommidbrain dopamine neurons and modulation of the quantal size. J. Neurosci. 18:4106-18
100. Baik JH. 2013. Dopamine signaling in reward-related behaviors. Front. Neural Circuits 7:152
101. Centonze D, Picconi B, Baunez C, Borrelli E, Pisani A, et al. 2002. Cocaine and amphetamine depress striatal GABAergic synaptic transmission throughD2 dopamine receptors. Neuropsychopharmacology 26:164-75
102. KimmelRA, TurnbullDH, BlanquetV,WurstW,Loomis CA, JoynerAL. 2000. Twolineage boundaries coordinate vertebrate apical ectodermal ridge formation. Genes Dev. 14:1377-89
103. Anzalone A, Lizardi-Ortiz JE, Ramos M, De Mei C, Hopf FW, et al. 2012. Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J. Neurosci. 32:9023-34
104. Lemberger T, Parlato R, Dassesse D, Westphal M, Casanova E, et al. 2007. Expression of Cre recombinase in dopaminoceptive neurons. BMC Neurosci. 8:4
105. Kieffer BL, Gaveriaux-Ruff C. 2002. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66:285-306
106. Scherrer G, Tryoen-Tóth P, Filliol D, Matifas A, Laustriat D, et al. 2006. Knockin mice expressing fluorescent opioid receptors uncover G protein-coupled receptor dynamics in vivo. PNAS 103:9691-96
107. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, et al. 2009. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137:1148-59
108. Shenoy SK, Lefkowitz RJ. 2011.-arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32:521-33
109. Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, et al. 2009. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLOS ONE 4:e5425
110. Faget L, Erbs E, Le Merrer J, Scherrer G, Matifas A, et al. 2012. In vivo visualization of delta opioid receptors upon physiological activation uncovers a distinct internalization profile. J. Neurosci. 32:7301-10
111. Dunkelberger J, Zhou L, Miwa T, Song WC. 2012. C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity. J. Immunol. 188:4032-42
112. Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, et al. 2008. Engineering GPCR signaling pathways with RASSLs. Nat. Methods 5:673-78
113. Coward P, Wada HG, Falk MS, Chan SD, Meng F, et al. 1998. Controlling signaling with a specifically designed Gi-coupled receptor. PNAS 95:352-57
114. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, et al. 1999. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat. Biotechnol. 17:165-69
115. Peng J, Bencsik M, Louie A, Lu W, Millard S, et al. 2008. Conditional expression of a Gi-coupled receptor in osteoblasts results in trabecular osteopenia. Endocrinology 149:1329-37
116. Hsiao EC, Boudignon BM, Chang WC, Bencsik M, Peng J, et al. 2008. Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. PNAS 105:1209-14
117. Chang WC, Ng JK, Nguyen T, Pellissier L, Claeysen S, et al. 2007. Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLOS ONE 2:e1317
118. Srinivasan S, Santiago P, Lubrano C, Vaisse C, Conklin BR. 2007. Engineering the melanocortin-4 receptor to control constitutive and ligand-mediated GS signaling in vivo. PLOS ONE 2:e668
119. Claeysen S, Joubert L, SebbenM, Bockaert J, Dumuis A. 2003. A single mutation in the 5-HT4 receptor (5-HT4-R D100(3. 32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). J. Biol. Chem. 278:699-702
120. BruystersM, Jongejan A, Akdemir A, Bakker RA, Leurs R. 2005. A Gq/11-coupled mutant histamine H1 receptor F435A activated solely by synthetic ligands (RASSL). J. Biol. Chem. 280:34741-46
121. Armbruster BN, Li X, PauschMH, Herlitze S, Roth BL. 2007. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. PNAS 104:5163-68
122. Urban DJ, Roth BL. 2015. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu. Rev. Pharmacol. Toxicol. 55:399-417
123. Dong S, Rogan SC, Roth BL. 2010. Directed molecular evolution of DREADDs: A generic approach to creating next-generation RASSLs. Nat. Protoc. 5:561-73
124. Alvarez-Curto E, Prihandoko R, Tautermann CS, Zwier JM, Pediani JD, et al. 2011. Developing chemical genetic approaches to exploreGprotein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). Mol. Pharmacol. 80:1033-46
125. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, et al. 2004. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:207-16
126. Bender D, Holschbach M, Stocklin G. 1994. Synthesis of n. c. A. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in mice. Nuclear Med. Biol. 21:921-25
127. ChangWH, Lin SK, Lane HY,Wei FC, Hu WH, et al. 1998. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 22:723-39
128. Dong S, Allen JA, Farrell M, Roth BL. 2010. A chemical-genetic approach for precise spatio-temporal control of cellular signaling. Mol. Biosyst. 6:1376-80
129. Guettier JM, Gautam D, Scarselli M, Ruiz de Azua I, Li JH, et al. 2009. A chemical-genetic approach to study G protein regulation ofcell function in vivo. PNAS 106:19197-202
130. Jain S, Ruiz de Azua I, Lu H, White MF, Guettier JM, Wess J. 2013. Chronic activation of a designer Gq-coupled receptor improvescell function. J. Clin. Investig. 123:1750-62
131. Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, et al. 2009. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63:27-39
132. Li H, Penzo MA, Taniguchi H, Kopec CD, Huang ZJ, Li B. 2013. Experience-dependent modification of a central amygdala fear circuit. Nat. Neurosci. 16:332-39
133. Garner AR, Rowland DC, Hwang SY, Baumgaertel K, Roth BL, et al. 2012. Generation of a synthetic memory trace. Science 335:1513-16
134. Parnaudeau S, O'Neill PK, Bolkan SS, Ward RD, Abbas AI, et al. 2013. Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition. Neuron 77:1151-62
135. Kong D, Tong Q, Ye C, Koda S, Fuller PM, et al. 2012. GABAergic RIP-Cre neurons in the arcuate nucleus selectively regulate energy expenditure. Cell 151:645-57
136. Hudson BD, Christiansen E, Tikhonova IG, Grundmann M, Kostenis E, et al. 2012. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J. 26:4951-65
137. Hudson BD, Smith NJ, Milligan G. 2011. Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. Adv. Pharmacol. 62:175-218
138. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. 2005. Millisecond-timescale, genetically targeted optical control of neural activity. Nat. Neurosci. 8:1263-68
139. Fenno L, Yizhar O, Deisseroth K. 2011. The development and application of optogenetics. Annu. Rev. Neurosci. 34:389-412
140. Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. 2011. Optogenetics in neural systems. Neuron 71:9-34
141. Xie YF, Jackson MF, Macdonald JF. 2013. Optogenetics and synaptic plasticity. Acta Pharmacol. Sinica 34:1381-85
142. Lin JY, Sann SB, Zhou K, Nabavi S, Proulx CD, et al. 2013. Optogenetic inhibition of synaptic release with chromophore-assisted light inactivation (CALI). Neuron 79:241-53
143. Beiert T, Bruegmann T, Sasse P. 2014. Optogenetic activation of Gq signalling modulates pacemaker activity of cardiomyocytes. Cardiovasc. Res. 102:507-16
144. Deisseroth K. 2011. Optogenetics. Nat. Methods 8:26-29
145. Airan RD, Thompson KR, Fenno LE, Bernstein H, Deisseroth K. 2009. Temporally precise in vivo control of intracellular signalling. Nature 458:1025-29
146. Oh E, Maejima T, Liu C, Deneris E, Herlitze S. 2010. Substitution of 5-HT1A receptor signaling by a light-activated G protein-coupled receptor. J. Biol. Chem. 285:30825-36
147. Conn PJ, Pin JP. 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:205-37
148. Levitz J, PantojaC,Gaub B, JanovjakH, Reiner A, et al. 2013. Optical control ofmetabotropic glutamate receptors. Nat. Neurosci. 16:507-16
149. Rajagopal S, Rajagopal K, Lefkowitz RJ. 2010. Teaching old receptors new tricks: biasing seventransmembrane receptors. Nat. Rev. Drug Discov. 9:373-86
150. Reiter E, LefkowitzRJ. 2006. GRKs and-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17:159-65
151. Bristow MR. 2000. Adrenergic receptor blockade in chronic heart failure. Circulation 101:558-69
152. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, et al. 2010. Selectively engaging arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335:572-79
153. Eglen RM. 2006. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton. Autacoid Pharmacol. 26:219-33
154. Tobin AB, Nahorski SR. 1993. Rapid agonist-mediated phosphorylation of m3-muscarinic receptors revealed by immunoprecipitation. J. Biol. Chem. 268:9817-23
155. Budd DC, Willars GB, McDonald JE, Tobin AB. 2001. Phosphorylation of the Gq/11-coupled M3-muscarinic receptor is involved in receptor activation of the ERK-1/2 mitogen-activated protein kinase pathway. J. Biol. Chem. 276:4581-87
156. Kong KC, Butcher AJ, McWilliams P, Jones D, Wess J, et al. 2010. M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. PNAS 107:21181-86
157. Poulin B, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, et al. 2010. The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. PNAS 107:9440-45
158. Gautam D, Han SJ, Duttaroy A, Mears D, Hamdan FF, et al. 2007. Role of the M3 muscarinic acetylcholine receptor in cell function and glucose homeostasis. Diabetes Obes. Metab. 9(Suppl. 2):158-69
159. Kong KC, Tobin AB. 2011. The role ofM3-muscarinic receptor signaling in insulin secretion. Commun. Integr. Biol. 4:489-91